Last reviewed · How we verify
Standard Dose of Myfortic and Reduced Dose of Myfortic
Standard Dose of Myfortic and Reduced Dose of Myfortic is a Small molecule drug developed by Samsung Medical Center. It is currently FDA-approved. Also known as: Kidney Graft Function under the Immunosuppression Strategies.
At a glance
| Generic name | Standard Dose of Myfortic and Reduced Dose of Myfortic |
|---|---|
| Also known as | Kidney Graft Function under the Immunosuppression Strategies |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- COVID Protection After Transplant-Immunosuppression Reduction (PHASE2)
- Optimizing PTCy Dose and Timing (PHASE1, PHASE2)
- Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (PHASE2)
- Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis (NA)
- Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation (PHASE2)
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Dose of Myfortic and Reduced Dose of Myfortic CI brief — competitive landscape report
- Standard Dose of Myfortic and Reduced Dose of Myfortic updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about Standard Dose of Myfortic and Reduced Dose of Myfortic
What is Standard Dose of Myfortic and Reduced Dose of Myfortic?
Standard Dose of Myfortic and Reduced Dose of Myfortic is a Small molecule drug developed by Samsung Medical Center.
Who makes Standard Dose of Myfortic and Reduced Dose of Myfortic?
Standard Dose of Myfortic and Reduced Dose of Myfortic is developed and marketed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).
Is Standard Dose of Myfortic and Reduced Dose of Myfortic also known as anything else?
Standard Dose of Myfortic and Reduced Dose of Myfortic is also known as Kidney Graft Function under the Immunosuppression Strategies.
What development phase is Standard Dose of Myfortic and Reduced Dose of Myfortic in?
Standard Dose of Myfortic and Reduced Dose of Myfortic is FDA-approved (marketed).
Related
- Manufacturer: Samsung Medical Center — full pipeline
- Also known as: Kidney Graft Function under the Immunosuppression Strategies
- Compare: Standard Dose of Myfortic and Reduced Dose of Myfortic vs similar drugs
- Pricing: Standard Dose of Myfortic and Reduced Dose of Myfortic cost, discount & access